Section Arrow
Quote
GH.NASDAQ
- Guardant Health
Quotes are at least 15-min delayed:2024/05/13 16:51 EDT
Last
 24
+1.63 (+7.29%)
Day High 
24.19 
Prev. Close
22.37 
1-M High
22.51 
Volume 
4.17M 
Bid
23.6
Ask
24.3
Day Low
22.3681 
Open
22.7 
1-M Low
15.81 
Market Cap 
2.73B 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 19.03 
20-SMA 18.01 
50-SMA 18.39 
52-W High 41.06 
52-W Low 15.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.28/-2.43
Enterprise Value
4.05B
Balance Sheet
Book Value Per Share
0.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
563.95M
Operating Revenue Per Share
4.40
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ME23andMe Holding Co0.5291+0.0316+6.35%-- 
GHGuardant Health24+1.63+7.29%-- 
EXASExact Sciences Corp55.59+2.08+3.89%-- 
OPKOPKO Health1.26-0.02-1.56%-- 
NEOGNeogen Corp12.84+0.51+4.14%616.5PE
Quotes are at least 15-min delayed：2024/05/13 16:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD,test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.